Hoon Jeong Ji, Christensen Lane V, Yockman James W, Zhong Zhiyuan, Engbersen Johan F J, Jong Kim Won, Feijen Jan, Wan Kim Sung
CCCD/Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, UT 84112, USA.
Biomaterials. 2007 Apr;28(10):1912-7. doi: 10.1016/j.biomaterials.2006.12.019. Epub 2007 Jan 10.
Designing synthetic macromolecular vehicles with high transfection efficiency and low cytotoxicity has been a major interest in the development of non-viral gene carriers. A reducible poly(amido ethylenimine) (SS-PAEI) synthesized by addition copolymerization of triethylenetetramine and cystamine bis-acrylamide (poly(TETA/CBA)) was used as a carrier for small interference RNA (siRNA). Poly(TETA/CBA) could efficiently condense siRNA to form stable complexes under physiological conditions and perform complete release of siRNA in a reductive environment. When formulated with VEGF-directed siRNA, poly(TETA/CBA) demonstrated significantly higher suppression of VEGF than linear-polyethylenimine (PEI) (L-PEI, 25kDa) in human prostate cancer cells (PC-3). After 5h of transfection, substantial dissociation and intracellular distribution of siRNA was observed in the poly(TETA/CBA) formulation, but not in the L-PEI formulation. The triggered release of siRNA by reductive degradation of poly(TETA/CBA) in the cytoplasm may affect the RNAi activity by increasing cytoplasmic availability of siRNA. These results suggest that the rational design of non-viral carriers should involve considerations for intracellular dissociation and trafficking of a nucleic acid drug to maximize its effect, in conjunction with formation of stable complexes under physiological conditions.
设计具有高转染效率和低细胞毒性的合成高分子载体一直是开发非病毒基因载体的主要研究方向。通过三亚乙基四胺和胱胺双丙烯酰胺(聚(TETA/CBA))加成共聚合成的可还原聚(酰胺基乙撑亚胺)(SS-PAEI)被用作小干扰RNA(siRNA)的载体。聚(TETA/CBA)在生理条件下能有效浓缩siRNA形成稳定复合物,并在还原环境中实现siRNA的完全释放。当与VEGF靶向的siRNA一起配制时,聚(TETA/CBA)在人前列腺癌细胞(PC-3)中对VEGF的抑制作用明显高于线性聚乙烯亚胺(PEI)(L-PEI,25kDa)。转染5小时后,在聚(TETA/CBA)制剂中观察到siRNA的大量解离和细胞内分布,但在L-PEI制剂中未观察到。聚(TETA/CBA)在细胞质中通过还原降解触发siRNA的释放,可能通过增加siRNA在细胞质中的可用性来影响RNAi活性。这些结果表明,非病毒载体的合理设计应考虑核酸药物在细胞内的解离和运输,以最大限度地发挥其作用,同时在生理条件下形成稳定复合物。